Kornimate/medical-research-clean huggingface dataset:
diode laser study for periodontal maintenance patients

Conditions: Periodontal Diseases; Periodontitis, Apical, Chronic Nonsuppurative; Suppuration of Gingival Crevice

Summary: this study tries to determine whether the additional use of laser with "cleaning" (known as scaling and root planning) will result in the reduction of inflammation, reduction of bleeding upon examination and reduction of pocket depth in patients who are being maintained on a regular basis but have pocket depths that are ≥5mm with bleeding. when a pocket is bleeding, it is inflamed. it is usually "cleaned" with periodontal instruments (root-planed) to establish health. some research also advocates using laser therapy to treat a bleeding pocket. laser therapy is presently being performed in some dental offices and dental colleges. this research is trying to see if the additional laser therapy is beneficial.

the purpose of this study is to determine whether the adjunctive use of diode laser with scaling and root planing is more effective than scaling and root planing alone in clinically reducing periodontal pocket depth (pd), reducing bleeding on probing (bop) and gaining of clinical attachment level (cal). it also assesses whether diode laser with scaling and root planing will have an effect on cytokines and inflammatory biomarkers compared to root planing alone. any adult who is currently a routine periodontal maintenance patient and has one or more ≥ 5mm pockets with bop will be invited to participate in the study. if they choose to participate, they will sign an informed consent. crevicular fluid samples from each test site and another non-involved site in the mouth will be collected utilizing the standard protocol and frozen for later analyses of the presence of certain inflammatory biomarkers (il-1β). baseline data (i.e., pd, cal, bop, suppuration, supragingival plaque, subgingival restorative margins, smoking status) will be collected. the involved teeth will then be randomly treated with scaling and root-planing with hand instruments and diode laser (test) or scaling and root-planing with hand instruments alone. the patient will return 3 months later for follow-up data collection. he/she will then receive his/her regular 3 month maintenance therapy. the changes between baseline and 3 months for the clinical parameters and gingival crevicular fluids' inflammatory biomarkers will be compared between test and control experimental sites.

Eligibility criteria:
inclusion criteria: * any adult periodontal maintenance patient having had chronic periodontitis with last active therapy at least 3 months prior and with 1 or more sites/subject with ≥5mm probing depth that have bleeding on probing and/or suppuration. they have signed an informed consent form to participate in the study. exclusion criteria: * subjects who are un-controlled diabetics, use nsaids regularly for chronic disease/pain, used antibiotics for the last 3 months, require antibiotic coverage for therapy, are pregnant and below age 30.

Keywords: periodontal maintenance ≥5mm probing depth bleeding on probing and/or suppuration
impact of 3d intraoral scanning on postsurgical evaluation of mandibular third molar surgery

Conditions: Third Molar Surgery; Impacted Third Molar Tooth

Summary: the aim of this study was to analyze the effectiveness of piezoelectric surgery and traditional rotating device in reducing perioperative sequelae after impacted mandibular third molar surgery in 56 subjects. ni all subjects were randomly allocated to receive one treatment.

the aim of this study was to analyze the effectiveness of piezoelectric surgery and traditional rotating device in reducing perioperative sequelae after impacted mandibular third molar surgery. fifty-six patients who needed surgical extraction of an impacted mandibular third molar were selected for the study. all subjects were randomly allocated to receive one of the following surgical treatments piezoelectric surgery (n = 28), traditional surgery with rotating device (n = 28). the primary outcome was postoperative pain, evaluated using the visual analogue scale (vas) score at baseline, 1, 2, 5, 7, 10 and 14 and 28 days following surgery. the secondary outcomes chosen were changes in postoperative swelling and maximum mouth opening values compared to preoperative ones.

Eligibility criteria:
inclusion criteria: * aged between 18 and 32 years; * good general health; * the presence of one impacted third molar in the mandible with a class ii position, type b impaction; * absence of pericoronitis or signs of inflammation during the last 30 days. panoramic radiographs were used to determine tooth position. exclusion criteria: * the presence of any systemic disease; * consumption of oral contraceptives or other medications; * consumption of any immunosuppressive or anti-inflammatory drugs during the 3 months prior to the study; * status of pregnancy or lactation; * previous history of excessive drinking; * allergy to local anesthetic; * smoking habit.
pain clinic staff harassed by patients pre/post covid

Conditions: Patient Violence

Summary: chronic pain may cause psychological or behavioral problems. chronic pain patients occasionally harass the pain care providers. the covid-19 pandemic caused major stress for the general population. quantitative and qualitative analysis of prospective electronic and clinic diary data. evaluation of incidents of clinic staff harassment; caused by patients, before and during covid pandemic. analysis of causative factors, incident outcome and lessons learned.

chronic pain may be complicated by mental disease. some patients have behavioral disorders and occasionally harass the pain care providers. the covid-19 pandemic caused significant stress for the general population. the stress of the pandemic may aggravate the psychological dysfunction in chronic pain patients. this is a quantitative and qualitative analysis of prospective electronic and clinic diary data. it is an evaluation of incidents of pain clinic staff harassment; caused by patients, before and during the covid pandemic. this is an analysis of incident causative factors, incident outcomes, systemic factors and lessons learned. the qualitative information of each incident is presented in a sensitive and careful format.

Eligibility criteria:
inclusion criteria: * adult chronic pain patients exclusion criteria: * pediatric chronic pain patients

Keywords: harassment by patient
the beacon study (breast cancer outcomes with nktr-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer

Summary: the study is designed as an open-label, randomized, parallel, two arm, multicenter, international phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. the primary study objective is to compare overall survival of patients who receive nktr-102 given once every 21 days to patients who receive treatment of physician's choice selected from a list of seven single-agent intravenous therapies.


Eligibility criteria:
inclusion criteria (major highlights): * patient is an adult female with histologically or cytologically confirmed carcinoma of the breast for whom single-agent cytotoxic chemotherapy is indicated * patient can have either measurable or non-measurable disease by recist. * patient has received prior therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) with an anthracycline, a taxane and capecitabine * patient has minimum of 2 and a maximum of 5 prior cytotoxic chemotherapy regimens with the last dose administered within 6 months. a minimum of two chemotherapy regimens had to be for locally recurrent and/or metastatic disease. all therapy received prior to a diagnosis of metastatic disease (eg, neoadjuvant, adjuvant or repeated adjuvant therapy following a second resection) is counted as one regimen. * patient has eastern cooperative oncology group (ecog) performance status of 0 or 1. * adequate hematopoietic, liver and kidney functions. exclusion criteria (major highlights): * patient with chemotherapy within 21 days, radiotherapy within 14 days, biological therapy with 14 days, hormonal therapy within 7 days and investigational therapy within 21 days prior to randomization. * patient with any major surgery within 28 days prior to randomization. * patient with concurrent use of biologic agents for the treatment of cancer including antibodies or any investigational agent(s). * patient with prior treatment for cancer with a camptothecin derivative. * patient with chronic or acute gi disorders resulting in diarrhea of any severity grade; patients who are using chronic anti-diarrheal supportive care to control diarrhea in the 28 days prior to randomization. * patient received pharmacotherapy for hepatitis b or c, tuberculosis or hiv. * patient with known cirrhosis diagnosed with child-pugh class a or higher liver disease. * patient with prior malignancy (other than breast cancer) except for non-melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 5 years prior to randomization. * patient requiring daily use of oxygen supplementation in the 28 days prior to randomization. * patients with significant cardiovascular impairment.
studies of the tumour suppressor gene pten - endometrial cancer

Conditions: Endometrial Neoplasms

Summary: this project seeks to understand the role of the pten tumour suppressor gene in endometrial cancer (tumours of the uterine lining), the most common gynecologic cancer in the developed world. the studies in this program span the spectrum from fruit flies to humans, as part of a synergistic partnership that will significantly enhance our understanding of the molecular genetic events involved in the development and progression of endometrial cancer. the discovery of new targets for therapy, and the ability to evaluate these in subsequent clinical trials is a significant strength of this scientific interaction, which may result in cures for patients with primary and relapse endometrial cancer and prevention of this cancer in women who are at high risk.

pten is a critical module that regulates effects of sex hormones on the growth and apoptosis of endometrial cells; and plays an important role in the pathogenesis of subgroups of endometrial cancers, their biologic behaviour and responses to therapeutic agents. furthermore, mutational inactivation of the pten gene can serve as an independent molecular marker that can predict relapse and survival in endometrial cancer. the prognostic effects of pten may also be modulated by other tumour suppressor gene losses including p53 mutations, by hormone receptor status, and microsatellite instability.

Eligibility criteria:
inclusion criteria: * age 18 and older * patients who had a hysterectomy * patient able to provide consent and complete questionnaire
randomized trial evaluating the effectiveness of the general practitioner involvement in cancer screening invitations

Conditions: Breast Cancer; Colorectal Cancer; Cervical Cancer

Summary: our goal is to evaluate, in france, the effectiveness (in terms of participation) of the general practitioner involvement (signature) and a more personalized communication in invitation letters to organized screening of breast, colorectal and cervical cancers. the hypothesis on which this project is based is that communication is probably more effective if the "receiver" feels personally targeted by invitation letters (dear martin, i am writing ...) and if he knows "the issuer "(his general practitioner rather an unknown person).


Eligibility criteria:
inclusion criteria: * living in indre-et-loire (french territorial division 37) * be affiliated to the following three health insurance companies: cpam (caisse primaire d'assurance maladie), msa (mutualité sociale agricole), or rsi (régime social des indépendants) * having declared (to health insurance company) an attending physician who has given its written consent to participate in the study * present no exclusion criterion to cancer screening ( for each one) * be old from 50 to 74 years (breast and colorectal cancer) or from 25 to 65 years (cervical cancer) exclusion criteria:

Keywords: general practitioner screening participation organized screening
angiotensin (1-7) for the treatment of covid-19 in hospitalized patients

Conditions: Covid19

Summary: the primary objective is to evaluate the safety and efficacy of intravenous (iv) infusion of ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for mechanical ventilation or extracorporeal membrane oxygenation (ecmo), and mortality in patients with covid 19.


Eligibility criteria:
inclusion criteria: * signs and symptoms suggestive of covid-19 infection including cough or dyspnea * laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) test ≤7 days before randomization * currently hospitalized or in an emergency department with planned hospitalization * peripheral capillary oxygen saturation (spo2) ≤93% on room air or partial pressure of oxygen (pao2)/fraction of inspired oxygen (fio2) \<300 at screening exclusion criteria: * simultaneous participation in any other clinical study incompatible with this one * treatment with an antibody immunotherapy that is not standard of care for covid-19 within 4 weeks of screening * requirement for mechanical ventilation or ecmo at screening * hypotension at screening, defined as supine bp \<95 mm hg systolic or \<55 mm hg diastolic * severe liver injury defined as ast or alt ≥5x the upper limit of normal * severe kidney failure defined as an estimated glomerular filtration rate (egfr) \<30 ml/min * any known immune deficiency * pregnancy or breastfeeding
internet-behavioral cough suppression therapy

Conditions: Cough; Chronic Disease

Summary: the goal of this randomized, placebo-controlled, clinical trial is to develop and test the efficacy of an internet-based behavioral intervention for refractory chronic cough. the main questions it aims to answer are: * what are the best recruitment pathways to find people living with refractory chronic cough in montana? * is internet-behavioral cough suppression therapy (ibcst) efficacious? * do ibcst participants find it satisfactory? * is using hyfe research app to monitor cough frequency feasible in rural areas? participants will complete ibcst or a placebo treatment virtually. some participants will take part in qualitative interviews and use hyfe research app for ambulatory cough frequency monitoring.


Eligibility criteria:
inclusion criteria: * no barriers to using a computer or smartphone (e.g., no significant fine motor or visual problems). * internet and e-mail access and the ability to use it. * suffering from a cough lasting at least eight weeks that is: * largely unproductive (cough up no more than a few teaspoons worth of clear or white sputum or mucus in a 24-hour period). * report of cough triggered by identifiable stimuli including and not limited to any combination of the following: cold air, talking, laughing, taking a deep breath, exercise, crumbly foods, strong smells or odors, fumes from paint or cleaning sprays. * often preceded by the sensation of an urge-to-cough (e.g., tickle or itch) at the level of the throat. * self-report of receiving the following assessments for current cough symptoms with unremarkable results: * physical evaluation by at least one physician. * chest x-ray. * willingness to avoid other potential cough treatments during the course of the study (or alert study personnel if alternative treatment is implemented out of necessity). exclusion criteria: * current smoker of any substance. * diagnosis of any of the following: * respiratory disease (e.g., chronic obstructive pulmonary disease, asthma) * neurogenic disease (e.g., parkinson's disease, cerebrovascular disease) * head and neck cancer * self-report of difficulty swallowing since having chronic cough * use of the following medication: * angiotensin-converting enzyme inhibitor (ace-i) in the past four weeks: benzapril (lotensin), captopril (capoten), enalapril/enalaprilat (vasotec oral and injectable), fosinopril (monopril), lisinopril (zestril and prinivil), moexipril (univasc), perindopril (aceon), quinapril (accupril), ramipril (altace), and trandolapril (mavik). * use of a neuromodulator medication in the past 48 hours: neurontin (gabapentin) and amitriptyline. * individuals with dysphonia (abnormal voice; either self-reported or perceived by study personnel during enrollment interview) will be excluded unless they have had a normal laryngoscopy (endoscopic assessment of the larynx) by an otolaryngologist (ent) within the past year specifically for their cough.

Keywords: refractory chronic cough behavioral cough suppression therapy
efficacy and safety of escócia association in the treatment of acute pain

Conditions: Acute Pain

Summary: the purpose of this study is to evaluate the efficacy and safety of escócia association in adults with acute pain.


Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * participants, aged 18 years and older, with renal colic admitted in the emergency service, or those who underwent an extracorporeal lithotripsy procedure to eliminate kidney stones. exclusion criteria: * known hypersensitivity to the formula components used during the clinical trial; * history of alcohol and/or substance abuse within 2 years; * pregnant women, breastfeeding or planning to become pregnant, or women with the potential to become pregnant who are not using a reliable method of contraception; * participants weighing less than 50 kg; * participants with suspected other causes of acute abdominal pain; * participants with a known history of peptic ulcer, gastrointestinal bleeding, perforation or inflammatory bowel disease; * participants with hypovolemia or dehydration; * renal failure, defined by the estimated glomerular filtration rate \[egfr\] \<60 ml / min / 1.73 m2; * participants with a known medical history of cerebrovascular bleeding, hemorrhagic diathesis (hemophilia), blood clotting disorders; postoperative of coronary artery bypass graft surgery, or using anticoagulants, including low heparin dose (2500-5000 units every 12 hours); * participants in the postoperative period with a high risk of bleeding or incomplete homeostasis; * participants with cardiovascular disease, chronic heart failure or with increased risk of cardiovascular events are at the discretion of the investigator, in order to include the participant; * participants with a current medical history of cancer and / or cancer treatment in the last 5 years; * participants using pentoxifylline, probenecid or lithium salts; * participants with megacolon and / or paralytic or obstructive ileus; * participants with glaucoma and myasthenia gravis; * participants on treatment with mao inhibitors, or participants who have been treated with these drugs within 14 days; * participants on epilepsy not adequately controlled treatment.
impedance vs. contact force guided atrial fibrillation ablation using automated annotation system

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to compare the efficacy of catheter ablation for atrial fibrillation between contact force-guided and impedance-guided annotation using automated annotation system (visitag™). patients who receive atrial fibrillation ablation are randomly assigned in the same number to two groups with impedance guided ablation and contact force guided ablation using contact force sensing catheter (thermocool® smarttouch™ catheter, biosense webster, inc., diamond bar, ca).

during atrial fibrillation ablation, the location where ablation is conducted is displayed through annotation tags using 3d system to recognize energy delivery is done at the area. however this annotation method was unable to identify how effectively the ablation is done. to remedy this disadvantage, automated annotation system (visitag™ module, biosense webster, inc., diamond bar, ca) was recently developed to make an automatic annotation when all pre-defined criteria are satisfied. but study on the clinical effects of this system is insufficient. the purpose of this study is to compare the efficacy of catheter ablation for atrial fibrillation between contact force-guided and impedance-guided annotation using automated annotation system.

Eligibility criteria:
inclusion criteria: * patients with non-valvular atrial fibrillation * patients having atrial fibrillation even after receiving continued treatment with at least 1 antiarrhythmic drug for more than 6 weeks * patients with tachycardia-bradycardia syndrome associated with atrial fibrillation. * patients who can understand the information sheet and consent form on the need and procedure of catheter ablation and submitted them * patients who are available of follow-up at least for more than three months after catheter ablation exclusion criteria: * patients unsuitable for catheter ablation because the size of left atrium is over 5.5cm * patients unsuitable for catheter ablation due to previous history of pulmonary surgery or structural heat disease. * patients who cannot receive standard treatments such as anticoagulation therapy which need to be continuously performed prior to radiofrequency catheter ablation * patients in the subject group vulnerable to clinical study * patients who had undergone a prior catheter ablation for atrial fibrillation

Keywords: atrial fibrillation catheter ablation